Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus

Caroline M. Finn,K. Kai McKinstry

DOI: https://doi.org/10.3390/cells13070639

IF: 6

2024-04-06

Cells

Abstract:Current Influenza A virus (IAV) vaccines, which primarily aim to generate neutralizing antibodies against the major surface proteins of specific IAV strains predicted to circulate during the annual 'flu' season, are suboptimal and are characterized by relatively low annual vaccine efficacy. One approach to improve protection is for vaccines to also target the priming of virus-specific T cells that can protect against IAV even in the absence of preexisting neutralizing antibodies. CD4 T cells represent a particularly attractive target as they help to promote responses by other innate and adaptive lymphocyte populations and can also directly mediate potent effector functions. Studies in murine models of IAV infection have been instrumental in moving this goal forward. Here, we will review these findings, focusing on distinct subsets of CD4 T cell effectors that have been shown to impact outcomes. This body of work suggests that a major challenge for next-generation vaccines will be to prime a CD4 T cell population with the same spectrum of functional diversity generated by IAV infection. This goal is encapsulated well by the motto 'ex pluribus unum': that an optimal CD4 T cell response comprises many individual specialized subsets responding together.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the current problem of insufficient efficacy of influenza A virus (IAV) vaccines. The current IAV vaccines mainly aim to generate neutralizing antibodies against the major surface proteins (such as hemagglutinin HA and neuraminidase NA) of specific IAV strains. These vaccines need to be reformulated every year to deal with the predicted prevalent IAV strains. However, due to antigenic drift and antigenic shift, the match between the vaccine - induced antibodies and the actually prevalent IAV strains is often not high, resulting in relatively low annual efficacy of the vaccines.

To improve the protection effect, the paper proposes a new strategy, that is, to simultaneously activate virus - specific T cells, especially CD4 T cells, through vaccines. CD4 T cells can not only promote the responses of other innate and adaptive lymphocyte populations, but also directly mediate powerful effector functions. By activating these T cells, protection against IAV can be provided even in the absence of pre - existing neutralizing antibodies.

Specifically, the paper reviews the research progress in mouse models of IAV infection, focusing on how different subsets of CD4 T - cell effectors affect the infection outcome. Research shows that a major challenge for the next - generation vaccines will be to trigger a CD4 T - cell population with the same functional diversity as that generated by IAV infection. This goal can be summarized by the Latin phrase "ex pluribus unum", which means "out of many, one", that is, an optimal CD4 T - cell response consists of the joint responses of many specialized subsets.